[
1. de Haas M, Thurik FF, Koelewijn JM, et al. Haemolytic disease of the fetus and newborn. Vox Sang 2015;109:99–113.]Search in Google Scholar
[
2. Urbaniak SJ, Greiss MA. RhD haemolytic disease of the fetus and the newborn. Blood Rev 2000;14:44–61.]Search in Google Scholar
[
3. van ’t Oever RM, Zwiers C, de Winter D, et al. Identification and management of fetal anemia due to hemolytic disease. Expert Rev Hematol 2022;15:987–98.]Search in Google Scholar
[
4. De Winter DP, Hulzebos C, van ’t Oever RM, De Haas M, Verweij EJ, Lopriore E. History and current standard of postnatal management in hemolytic disease of the fetus and newborn. Eur J Pediatr 2023;182:489–500.]Search in Google Scholar
[
5. Legler TJ. RhIg for the prevention Rh immunization and IVIg for the treatment of affected neonates. Transfus Apher Sci 2020;59:102950.]Search in Google Scholar
[
6. van der Schoot CE, Oepkes D. Non-invasive prenatal testing of Rh fetal status. In: Visser GHA, Di Renzo GC, Eds. The prevention and management of Rh disease. Vol. 16. Global Library of Women’s Medicine, 2022. ISSN: 1756-2228. DOI 10.3843/GLOWM.418913.]Search in Google Scholar
[
7. Moise KJ Jr. Management of rhesus alloimmunization in pregnancy. Obstet Gynecol 2008;112:164–76.]Search in Google Scholar
[
8. de Haas M, Finning K, Massey E, et al. Anti-D prophylaxis: past, present and future. Transfus Med 2014;24:1–7.]Search in Google Scholar
[
9. Dziegiel MH, Krog GR, Hansen AT, et al. Laboratory monitoring of mother, fetus, and newborn in hemolytic disease of fetus and newborn. Transfus Med Hemother 2021;48:306–15.]Search in Google Scholar
[
10. Moise KJ Jr, Argoti PS. Management and prevention of red cell alloimmunization in pregnancy: a systematic review. Obstet Gynecol 2012;120:1132–9.]Search in Google Scholar
[
11. van der Schoot CE, D Winkelhorst, FB Clausen. Non-invasive fetal blood group typing. In: Page-Christiaens L, Klein H-G, Eds. Noninvasive prenatal testing (NIPT): applied genomics in prenatal screening and prenatal diagnosis. Amsterdam: Elsevier, 2018:125–56.]Search in Google Scholar
[
12. van der Schoot CE, de Haas M, Clausen FB. Genotyping to prevent Rh disease: has the time come? Curr Opin Hematol 2017;24:544–50.]Search in Google Scholar
[
13. Hyland CA, O’Brien H, Flower RL, Gardener GJ. Non-invasive prenatal testing for management of haemolytic disease of the fetus and newborn induced by maternal alloimmunisation. Transfus Apher Sci 2020;59:102947.]Search in Google Scholar
[
14. Haimila K. Overview of non-invasive fetal blood group genotyping. Ann Blood 2023;8:5:1–11.]Search in Google Scholar
[
15. Freeman K, Szczepura A, Osipenko L. Non-invasive fetal RHD genotyping tests: a systematic review of the quality of reporting of diagnostic accuracy in published studies. Eur J Obstet Gynecol Reprod Biol 2009;142:91–8.]Search in Google Scholar
[
16. Zhu YJ, Zheng YR, Li L, Zhou H, Liao X, Guo JX, Yi P. Diagnostic accuracy of non-invasive fetal RhD genotyping using cell-free fetal DNA: a meta analysis. J Matern Fetal Neonatal Med 2014;27:1839–44.]Search in Google Scholar
[
17. Lo YMD, Corbetta N, Chamberlain PF, et al. Presence of fetal DNA in maternal plasma and serum. Lancet 1997;350:485–7.]Search in Google Scholar
[
18. Alberry M, Maddocks D, Jones M, et al. Free fetal DNA in maternal plasma in anembryonic pregnancies: confirmation that the origin is the trophoblast. Prenat Diagn 2007;27:415–8.]Search in Google Scholar
[
19. Clausen FB. Lessons learned from the implementation of non-invasive fetal RHD screening. Expert Rev Mol Diagn 2018;18:423–31.]Search in Google Scholar
[
20. Runkel B, Bein G, Sieben W, Sow D, Polus S, Fleer D. Targeted antenatal anti-D prophylaxis for RhD-negative pregnant women: a systematic review. BMC Pregnancy Childbirth 2020;20:83.]Search in Google Scholar
[
21. Urbaniak SJ. The scientific basis of antenatal prophylaxis. BJOG 1998;105(Suppl 18):11–8.]Search in Google Scholar
[
22. Hirose TG, Mays DA. The safety of RhIG in the prevention of haemolytic disease of the newborn. J Obstet Gynaecol 2007;27:545–57.]Search in Google Scholar
[
23. Liumbruno GM, D’Alessandro A, Rea F, et al. The role of antenatal immunoprophylaxis in the prevention of maternal-foetal anti-Rh(D) alloimmunisation. Blood Transfus 2010;8: 8–16.]Search in Google Scholar
[
24. Bowman JM, Chown B, Lewis M, et al. Rh isoimmunization during pregnancy: antenatal prophylaxis. Can Med Assoc J 1978;118:623–7.]Search in Google Scholar
[
25. Bowman JM, Pollock JM. Antenatal prophylaxis of Rh isoimmunization: 28-weeks’-gestation service program. Can Med Assoc J 1978;118:627–30.]Search in Google Scholar
[
26. Crowther CA, Keirse MJ. Anti-D administration in pregnancy for preventing rhesus alloimmunisation. Cochrane Database Syst Rev 2000;(2):CD000020.]Search in Google Scholar
[
27. Turner RM, Lloyd-Jones M, Anumba DO, et al. Routine antenatal anti-D prophylaxis in women who are Rh(D) negative: meta-analyses adjusted for differences in study design and quality. PLoS One 2012;7:e30711.]Search in Google Scholar
[
28. Koelewijn JM, de Haas M, Vrijkotte TG, et al. One single dose of 200 microg of antenatal RhIG halves the risk of anti-D immunization and hemolytic disease of the fetus and newborn in the next pregnancy. Transfusion 2008;48:1721–9.]Search in Google Scholar
[
29. Tiblad E, Taune Wikman A, Ajne G, et al. Targeted routine antenatal anti-D prophylaxis in the prevention of RhD immunisation: outcome of a new antenatal screening and prevention program. PLoS One 2013;8:e70984.]Search in Google Scholar
[
30. Thorup E, Clausen FB, Petersen OB, Dziegiel MH. The effect of the nationwide implementation of targeted routine antenatal anti-D prophylaxis in Denmark. Ultrasound 2022; 60(Suppl 1):211.]Search in Google Scholar
[
31. Bills VL, Soothill PW. Fetal blood grouping using cell free DNA: an improved service for RhD negative pregnant women. Transfus Apher Sci 2014;50:148–53.]Search in Google Scholar
[
32. Kent J, Farrell A-M, Soothill P. Routine administration of anti-D: the ethical case for offering pregnant women fetal RHD genotyping and a review of policy and practice. BMC Pregnancy Childbirth 2014;14:87:1–4.]Search in Google Scholar
[
33. van der Schoot CE, Tax GH, Rijnders RJ, et al. Prenatal typing of Rh and Kell blood group system antigens: the edge of a watershed. Transfus Med Rev 2003;17:31–44.]Search in Google Scholar
[
34. Müller SP, Bartels I, Stein W, et al. The determination of the fetal D status from maternal plasma for decision making on Rh prophylaxis is feasible. Transfusion 2008;48:2292–301.]Search in Google Scholar
[
35. Finning K, Martin P, Summers J, et al. Effect of high throughput RHD typing of fetal DNA in maternal plasma on use of anti-RhD immunoglobulin in RhD negative pregnant women: prospective feasibility study. BMJ 2008;336:816–8.]Search in Google Scholar
[
36. Chitty LS, Finning K, Wade A, et al. Diagnostic accuracy of routine antenatal determination of fetal RHD status across gestation: population based cohort study. BMJ 2014;349:g5243.]Search in Google Scholar
[
37. Soothill P, Finning K, Latham T, et al. Use of cffDNA to avoid administration of anti-D to pregnant women when the fetus is RhD-negative: implementation in the NHS. BJOG 2015;122:1682–6.]Search in Google Scholar
[
38. Clausen FB, Christiansen M, Steffensen R, et al. Report of the first nationally implemented clinical routine screening for fetal RHD in D- pregnant women to ascertain the requirement for antenatal RhD prophylaxis. Transfusion 2012;52:752–8.]Search in Google Scholar
[
39. Clausen FB, Steffensen R, Christiansen M, et al. Routine noninvasive prenatal screening for fetal RHD in plasma of RhD-negative pregnant women: 2 years of screening experience from Denmark. Prenat Diagn 2014;34:1000–5.]Search in Google Scholar
[
40. Jakobsen MA, Rosbach HK, Dellgren C, Yazer M, Sprogøe U. Results of noninvasive prenatal RHD testing in gestation week 25 are not affected by maternal body mass index. Transfusion 2018;58:2421–5.]Search in Google Scholar
[
41. Clausen FB, Rieneck K, Krog GR, Bundgaard BS, Dziegiel MH. Noninvasive antenatal screening for fetal RHD in RhD negative women to guide targeted anti-D prophylaxis. Methods Mol Biol 2019;1885:347–59.]Search in Google Scholar
[
42. Wikman AT, Tiblad E, Karlsson A, et al. Noninvasive single-exon fetal RHD determination in a routine screening program in early pregnancy. Obstet Gynecol 2012;120:227–34.]Search in Google Scholar
[
43. Neovius M, Tiblad E, Westgren M, Kublickas M, Neovius K, Wikman A. Cost-effectiveness of first trimester non-invasive fetal RHD screening for targeted antenatal anti-D prophylaxis in RhD-negative pregnant women: a model-based analysis. BJOG 2016;123:1337–46.]Search in Google Scholar
[
44. Uzunel M, Tiblad E, Mörtberg A, Wikman A. Single-exon approach to non-invasive fetal RHD screening in early pregnancy: an update after 10 years’ experience. Vox Sang 2022;117:1296–301.]Search in Google Scholar
[
45. Sørensen K, Baevre MS, Tomter G, et al. The Norwegian experience with nationwide implementation of fetal RHD genotyping and targeted routine antenatal anti-D prophylaxis. Transfus Med 2021;31:314–21.]Search in Google Scholar
[
46. Stensrud M, Bævre MS, Alm IM, et al. Terminating routine cord blood RhD typing of the newborns to guide postnatal anti-D immunoglobulin prophylaxis based on the results of fetal RHD genotyping. Fetal Diagn Ther 2023;50:276–81.]Search in Google Scholar
[
47. Haimila K, Sulin K, Kuosmanen M, et al. Targeted antenatal anti-D prophylaxis program for RhD-negative pregnant women: outcome of the first two years of a national program in Finland. Acta Obstet Gynecol Scand 2017;96:1228–33.]Search in Google Scholar
[
48. Jernman R, Isaksson C, Haimila K et al. Time points and risk factors for RhD immunizations after the implementation of targeted routine antenatal anti-D prophylaxis: a retrospective nationwide cohort study. Acta Obstet Gynecol Scand 2021;100:1868–75.]Search in Google Scholar
[
49. Gudlaugsson B, Hjartardottir H, Svansdottir G, et al. Rhesus D alloimmunization in pregnancy from 1996 to 2015 in Iceland: a nation-wide population study prior to routine antenatal anti-D prophylaxis. Transfusion 2020;60:175–83.]Search in Google Scholar
[
50. de Haas M, Thurik FF, van der Ploeg CP, et al. Sensitivity of fetal RHD screening for safe guidance of targeted anti-D immunoglobulin prophylaxis: prospective cohort study of a nationwide programme in the Netherlands. BMJ 2016;355: i5789.]Search in Google Scholar
[
51. Schimanski B, Kräuchi R, Stettler J, et al. Fetal RHD screening in RH1 negative pregnant women: experience in Switzerland. Biomedicines 2023;11:2646:1–10.]Search in Google Scholar
[
52. National Institute for Health and Care Excellence (NICE). High-throughput non-invasive prenatal testing for fetal RHD genotype. Diagnostics guidance [DG25]. Available from https://www.nice.org.uk/guidance/dg25. Published 9 November 2016.]Search in Google Scholar
[
53. Daniels G, Finning K, Lozano M, et al. Vox Sanguinis International Forum on application of fetal blood grouping: summary. Vox Sang 2018;113:198–201.]Search in Google Scholar
[
54. Daniels G, Finning K, Lozano M, et al. Vox Sanguinis International Forum on application of fetal blood grouping. Vox Sang 2018;113:e26–35.]Search in Google Scholar
[
55. Toly-Ndour C, Huguet-Jacquot S, Mailloux A, et al. Rh disease prevention: the European perspective. ISBT Sci Ser 2021;16:106–18.]Search in Google Scholar
[
56. Londero D, Merluzzi S, Dreossi C, Barillari G. Prenatal screening service for fetal RHD genotyping to guide prophylaxis: the two-year experience of the Friuli Venezia Giulia region in Italy. Blood Transfus 2023;21:93–9.]Search in Google Scholar
[
57. Blomme S, Nollet F, Rosseel W, et al. Routine noninvasive prenatal screening for fetal Rh D in maternal plasma: a 2-year experience from a single center in Belgium. Transfusion 2022;62:1103–9.]Search in Google Scholar
[
58. Johnson JA, MacDonald K, Clarke G, et al. No. 343-Routine non-invasive prenatal prediction of fetal RHD genotype in Canada: the time is here. J Obstet Gynaecol Can 2017;39:366–73.]Search in Google Scholar
[
59. Ginige S, Daly J, Hyland C, et al. The role of non-invasive prenatal testing (NIPT) for fetal blood group typing in Australia. Aust N Z J Obstet Gynaecol 2022;62:33–6.]Search in Google Scholar
[
60. Goodspeed TA, Allyse M, Sayres LC, et al. Translating cell-free fetal DNA technology: structural lessons from non-invasive RhD blood typing. Trends Biotechnol 2013;31:7–9.]Search in Google Scholar
[
61. Moise KJ Jr, Hashmi SS, Markham K, Argoti PS, Bebbington M. Cell free fetal DNA to triage antenatal rhesus immune globulin: is it really cost-effective in the United States? Prenat Diagn 2019;39:238–47.]Search in Google Scholar
[
62. Ma KK, Rodriguez MI, Cheng YW, et al. Should cell-free DNA testing be used to target antenatal rhesus immune globulin administration? J Matern Fetal Neonatal Med 2016;29:1866–70.]Search in Google Scholar
[
63. Gajic-Veljanoski O, Li C, Schaink AK, et al. Noninvasive fetal RhD blood group genotyping: a systematic review of economic evaluations. J Obstet Gynaecol Can 2021;43:1416–25.]Search in Google Scholar
[
64. Szczepura A, Osipenko L, Freeman K. A new fetal RHD genotyping test: costs and benefits of mass testing to target antenatal anti-D prophylaxis in England and Wales. BMC Pregnancy Childbirth 2011;11:5.]Search in Google Scholar
[
65. Benachi A, Delahaye S, Leticee N, et al. Impact of non-invasive fetal RhD genotyping on management costs of rhesus-D negative patients: results of a French pilot study. Eur J Obstet Gynecol Reprod Biol 2012;162:28–32.]Search in Google Scholar
[
66. Hawk AF, Chang EY, Shields SM, et al. Costs and clinical outcomes of noninvasive fetal RhD typing for targeted prophylaxis. Obstet Gynecol 2013;122:579–85.]Search in Google Scholar
[
67. Darlington M, Carbonne B, Mailloux A, et al. Effectiveness and costs of non-invasive foetal RHD genotyping in rhesus-D negative mothers: a French multicentric two-arm study of 850 women. BMC Pregnancy Childbirth 2018;18:496.]Search in Google Scholar
[
68. Legler TJ, Müller SP, Haverkamp A, et al. Prenatal RhD testing: a review of studies published from 2006 to 2008. Transfus Med Hemother 2009;36:189–98.]Search in Google Scholar
[
69. Gordon LG, Hyland CA, Hyett JA, et al. Noninvasive fetal RHD genotyping of RhD negative pregnant women for targeted anti-D therapy in Australia: a cost-effectiveness analysis. Prenat Diagn 2017;37:1245–53.]Search in Google Scholar
[
70. Duplantie J, Gonzales OM, Bois A, et al. Cost-effectiveness of the management of Rh-negative pregnant women. J Obstet Gynaecol Can 2013;35:730–40.]Search in Google Scholar
[
71. Teitelbaum L, Metcalfe A, Clarke G, et al. Costs and benefits of non-invasive fetal RhD determination. Ultrasound Obstet Gynecol 2015;45:84–8.]Search in Google Scholar
[
72. Saramago P, Yang H, Llewellyn A, Palmer S, Simmonds M, Griffin S. High-throughput, non-invasive prenatal testing for fetal rhesus D genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis. BJOG 2018;125:1414–22.]Search in Google Scholar
[
73. Macher HC, Noguerol P, Medrano-Campillo P, et al. Standardization non-invasive fetal RHD and SRY determination into clinical routine using a new multiplex RT-PCR assay for fetal cell-free DNA in pregnant women plasma: results in clinical benefits and cost saving. Clin Chim Acta 2012;413:490–4.]Search in Google Scholar
[
74. Norton M, Ma K, Caughey AB, et al. Should free fetal DNA testing replace antenatal anti-D administration for prevention of rhesus alloimmunization? AJOG 2011;204(Suppl 1):S69.]Search in Google Scholar
[
75. Koby L, Grunbaum A, Benjamin A, et al. Anti-D in Rh(D)-negative pregnant women: are at-risk pregnancies and deliveries receiving appropriate prophylaxis? J Obstet Gynaecol Can 2012;34:429–35.]Search in Google Scholar
[
76. Visser GHA, Thommesen T, Di Renzo GC, Nassar AH, Spitalnik SL; FIGO Committee for Safe Motherhood, Newborn Health. FIGO/ICM guidelines for preventing Rhesus disease: a call to action. Int J Gynaecol Obstet 2021;152:144–7.]Search in Google Scholar
[
77. Clausen FB, Damkjær MB, Dziegiel MH. Noninvasive fetal RhD genotyping. Transfus Apher Sci 2014;50:154–62.]Search in Google Scholar
[
78. Scheffer PG, van der Schoot CE, Page-Christiaens GC, de Haas M. Noninvasive fetal blood group genotyping of rhesus D, c, E and of K in alloimmunised pregnant women: evaluation of a 7-year clinical experience. BJOG 2011;118:1340–8.]Search in Google Scholar
[
79. Orzińska A, Guz K, Dębska M, et al. 14 Years of Polish experience in non-invasive prenatal blood group diagnosis. Transfus Med Hemother 2015;42:361–4.]Search in Google Scholar
[
80. Clausen FB, Hellberg Å. External quality assessment of noninvasive fetal RHD genotyping. Vox Sang 2020;115: 466–71.]Search in Google Scholar
[
81. Clausen FB, Barrett AN; Noninvasive Fetal RHD Genotyping EQA2017 Working Group. Noninvasive fetal RHD genotyping to guide targeted anti-D prophylaxis: an external quality assessment workshop. Vox Sang 2019;114:386–93.]Search in Google Scholar
[
82. Ariga H, Ohto H, Busch MP, et al. Kinetics of fetal cellular and cell-free DNA in the maternal circulation during and after pregnancy: implications for noninvasive prenatal diagnosis. Transfusion 2001;41:1524–30.]Search in Google Scholar
[
83. Galbiati S, Smid M, Gambini D, et al. Fetal DNA detection in maternal plasma throughout gestation. Hum Genet 2005;117:243–8.]Search in Google Scholar
[
84. Ungerer V, Bronkhorst AJ, Holdenrieder S. Preanalytical variables that affect the outcome of cell-free DNA measurements. Crit Rev Clin Lab Sci 2020;57:484–507.]Search in Google Scholar
[
85. Clausen FB, Jakobsen TR, Rieneck K, et al. Pre-analytical conditions in non-invasive prenatal testing of cell-free fetal RHD. PLoS One 2013;8:e76990.]Search in Google Scholar
[
86. Hyland CA, Millard GM, O’Brien H, et al. Non-invasive fetal RHD genotyping for RhD negative women stratified into RHD gene deletion or variant groups: comparative accuracy using two blood collection tube types. Pathology 2017;49:757–64.]Search in Google Scholar
[
87. Barrett AN, Zimmermann BG, Wang D, Holloway A, Chitty LS. Implementing prenatal diagnosis based on cell-free fetal DNA: accurate identification of factors affecting fetal DNA yield. PLoS One 2011;6:e25202.]Search in Google Scholar
[
88. Clausen FB, Barrett AN, Advani HV, Choolani M, Dziegiel MH. Impact of long-term storage of plasma and cell-free DNA on measured DNA quantity and fetal fraction. Vox Sang 2020;115:586–94.]Search in Google Scholar
[
89. Clausen FB, Hellberg Å, Bein G, et al. Recommendation for validation and quality assurance of non-invasive prenatal testing for foetal blood groups and implications for IVD risk classification according to EU regulations. Vox Sang 2022;117:157–65.]Search in Google Scholar
[
90. Hyland CA, O’Brien H, McGowan EC, et al. The power of digital PCR in fetal blood group genotyping: a review. Ann Blood 2023;8:1–8.]Search in Google Scholar
[
91. Sillence KA, Roberts LA, Hollands HJ, et al. Fetal sex and RHD genotyping with digital PCR demonstrates greater sensitivity than real-time PCR. Clin Chem 2015;61:1399–407.]Search in Google Scholar
[
92. van der Schoot, C, Ait Soussan A, Woortmeijer H, Folman C, de Haas M, Veldhuisen B. Fetal RHD genotyping by droplet digital PCR for D variant mothers or children [abstract]. Vox Sang 2023;118(Suppl 1):6–118.]Search in Google Scholar
[
93. Moise KJ Jr, Gandhi M, Boring NH, et al. Circulating cell-free DNA to determine the fetal RHD status in all three trimesters of pregnancy. Obstet Gynecol 2016;128:1340–6.]Search in Google Scholar
[
94. Clausen FB, Urhammer E, Rieneck K, et al. How to evaluate PCR assays for the detection of low-level DNA. APMIS 2015;123:731–9.]Search in Google Scholar
[
95. Legler TJ, Lührig S, Korschineck I, Schwartz D. Diagnostic performance of the noninvasive prenatal FetoGnost RhD assay for the prediction of the fetal RhD blood group status. Arch Gynecol Obstet 2021;304:1191–6.]Search in Google Scholar
[
96. Kjeldsen-Kragh J, Hellberg Å. Noninvasive prenatal testing in immunohematology: clinical, technical and ethical considerations. J Clin Med 2022;11:2877.]Search in Google Scholar
[
97. Vivanti A, Benachi A, Huchet FX, et al. Diagnostic accuracy of fetal rhesus D genotyping using cell-free fetal DNA during the first trimester of pregnancy. Am J Obstet Gynecol 2016;215:606.e1–e5.]Search in Google Scholar
[
98. Isakson P, Pardi C. Evaluation of an automated platform for non-invasive single-exon fetal RHD genotyping early in pregnancy. Blood Transfus. 14 February 2023 [Epub ahead of print]. doi: 10.2450/2023.0267-22.]Search in Google Scholar
[
99. Boggione CT, Luján Brajovich ME, Mattaloni SM, et al. Genotyping approach for non-invasive foetal RHD detection in an admixed population. Blood Transfus 2017;15:66–73.]Search in Google Scholar
[
100. Javadi A, Veldhuisen B, de Haas M, et al. Evaluation of phocine herpesvirus (phhv) as an internal control for prenatal RhD genotyping in maternal plasma [abstract]. Vox Sang 2016;111(Suppl 1):246.]Search in Google Scholar
[
101. Jensen MPS, Damkjaer MB, Clausen FB, et al. Targeted rhesus immunoglobulin for RhD-negative women undergoing an induced abortion: a clinical pilot study. Acta Obstet Gynecol Scand 2019;98:1164–71.]Search in Google Scholar
[
102. Daniels G. Variants of RhD: current testing and clinical consequences. Br J Haematol 2013;161:461–70.]Search in Google Scholar
[
103. Keller MA. RH genetic variation and the impact for typing and personalized transfusion strategies: a narrative review. Ann Blood 2023;8:18.]Search in Google Scholar
[
104. Sandler SG, Flegel WA, Westhoff CM, et al. It’s time to phase in RHD genotyping for patients with a serologic weak D phenotype: College of American Pathologists Transfusion Medicine Resource Committee Work Group. Transfusion 2015;55:680–9.]Search in Google Scholar
[
105. Sandler SG, Chen LN, Flegel WA. Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the RHD genotype. Br J Haematol 2017;179:10–9.]Search in Google Scholar
[
106. Ji Y, Luo Y, Wen J, et al. Patients with Asian-type DEL can safely be transfused with RhD-positive blood. Blood 2023;141:2141–50.]Search in Google Scholar
[
107. Daniels G, Finning K, Martin P, et al. Fetal blood group genotyping from DNA from maternal plasma: an important advance in the management and prevention of haemolytic disease of the fetus and newborn. Vox Sang 2004;87:225–32.]Search in Google Scholar
[
108. Avent ND, Madgett TE, Lee ZE, Head DJ, Maddocks DG, Skinner LH. Molecular biology of Rh proteins and relevance to molecular medicine. Expert Rev Mol Med 2006;8:1–20.]Search in Google Scholar
[
109. Wagner FF, Flegel WA. Review: the molecular basis of the Rh blood group phenotypes. Immunohematology 2004;20:23–36.]Search in Google Scholar
[
110. Westhoff CM. The structure and function of the Rh antigen complex. Semin Hematol 2007;44:42–50.]Search in Google Scholar
[
111. Flegel WA. Molecular genetics of RH and its clinical application. Transfus Clin Biol 2006;13:4–12.]Search in Google Scholar
[
112. Daniels G, Green C, Smart E. Differences between RhD-negative Africans and RhD-negative Europeans. Lancet 1997;350:862–63.]Search in Google Scholar
[
113. Singleton BK, Green CA, Avent ND, et al. The presence of an RHD pseudogene containing a 37 base pair duplication and a nonsense mutation in Africans with the Rh D-negative blood group phenotype. Blood 2000;95:12–8.]Search in Google Scholar
[
114. Touinssi M, Chapel-Fernandes S, Granier T, Bokilo A, Bailly P, Chiaroni J. Molecular analysis of inactive and active RHD alleles in native Congolese cohorts. Transfusion 2009;49:1353–60.]Search in Google Scholar
[
115. Wagner FF, Moulds JM, Tounkara A, Kouriba B, Flegel WA. RHD allele distribution in Africans of Mali. BMC Genet 2003;4:14.]Search in Google Scholar
[
116. Stegmann TC, Veldhuisen B, Bijman R, et al. Frequency and characterization of known and novel RHD variant alleles in 37 782 Dutch D-negative pregnant women. Br J Haematol 2016;173:469–79.]Search in Google Scholar
[
117. Dufour P, Gerard C, Chantraine F, Minon JM. Investigation of discrepancies obtained during 15 years of non-invasive fetal RHD genotyping in apparent serologic RhD-negative pregnant women. Prenat Diagn 2022;42:1262–72.]Search in Google Scholar
[
118. Tammi SM, Tounsi WA, Sainio S, et al. Next-generation sequencing of 35 RHD variants in 16 253 serologically D- pregnant women in the Finnish population. Blood Adv 2020;4:4994–5001.]Search in Google Scholar
[
119. Grootkerk-Tax MGHM, Soussan AA, de Haas M, et al. Evaluation of prenatal RHD typing strategies on cell-free fetal DNA from maternal plasma. Transfusion 2006;46:2142–48.]Search in Google Scholar
[
120. Finning KM, Martin PG, Soothill PW, et al. Prediction of fetal D status from maternal plasma: introduction of a new noninvasive fetal RHD genotyping service. Transfusion 2002;42:1079–85.]Search in Google Scholar
[
121. van der Schoot CE, Soussan AA, Woortmeijer H, Folman C, de Haas M, Veldhuisen B. Fetal RHD genotyping by droplet digital PCR for D variant mothers or children (abstract). Vox Sang 2023;118(Suppl 1):94.PA26-L06.]Search in Google Scholar
[
122. Clausen FB, Krog GR, Rieneck K, et al. Evaluation of two real-time multiplex PCR screening assays detecting fetal RHD in plasma from RhD negative women to ascertain the requirement for antenatal RhD prophylaxis. Fetal Diagn Ther 2011;29:155–63.]Search in Google Scholar
[
123. Wikman A. Fetal RHD screening in clinical routine: experiences and considerations. Expert Rev 2018;7:1–14. Available from www.devyser.com/whitepapers.]Search in Google Scholar
[
124. Esteban R, Montero R, Flegel WA, et al. The D category VI type 4 allele is prevalent in the Spanish population. Transfusion 2006;46:616–23.]Search in Google Scholar
[
125. Finning K, Martin P, Daniels G. The use of maternal plasma for prenatal RhD blood group genotyping. Methods Mol Biol 2009;496:143–57.]Search in Google Scholar
[
126. Wang XD, Wang BL, Ye SL, et al. Non-invasive foetal RHD genotyping via real-time PCR of foetal DNA from Chinese RhD-negative maternal plasma. Eur J Clin Invest 2009;39:607–17.]Search in Google Scholar
[
127. Duan H, Li J, Jiang Z, Shi X, Hu Y. Noninvasive screening of fetal RHD genotype in Chinese pregnant women with serologic RhD-negative phenotype. Transfusion 2023;63:2152–8.]Search in Google Scholar
[
128. Takahashi K, Migita O, Sasaki A, et al. Amplicon sequencing-based noninvasive fetal genotyping for RHD-positive D antigen-negative alleles. Clin Chem 2019;65:1307–16.]Search in Google Scholar
[
129. Kolialexi A, Tounta G, Mavrou A. Noninvasive fetal RhD genotyping from maternal blood. Expert Rev Mol Diagn 2010;10:285–96.]Search in Google Scholar
[
130. Mackie FL, Hemming K, Allen S, Morris RK, Kilby MD. The accuracy of cell-free fetal DNA-based non-invasive prenatal testing in singleton pregnancies: a systematic review and bivariate meta-analysis. BJOG 2017;124:32–46.]Search in Google Scholar
[
131. Yang H, Llewellyn A, Walker R, et al. High-throughput, non-invasive prenatal testing for fetal rhesus D status in RhD-negative women: a systematic review and meta-analysis. BMC Med 2019;17:37.]Search in Google Scholar
[
132. Alshehri AA, Jackson DE. Non-invasive prenatal fetal blood group genotype and its application in the management of hemolytic disease of fetus and newborn: systematic review and meta-analysis. Transfus Med Rev 2021;35:85–94.]Search in Google Scholar
[
133. Günel T, Kalelioğlu I, Ermiş H, Aydinli K. Detection of fetal RhD gene from maternal blood. J Turk Ger Gynecol Assoc 2010;11:82–5.]Search in Google Scholar
[
134. Sbarsi I, Isernia P, Montanari L, Badulli C, Martinetti M, Salvaneschi L. Implementing non-invasive RHD genotyping on cell-free foetal DNA from maternal plasma: the Pavia experience. Blood Transfus 2012;10:34–8.]Search in Google Scholar
[
135. Grande M, Ordoñez E, Cirigliano V, et al. Clinical application of midtrimester non-invasive fetal RHD genotyping and identification of RHD variants in a mixed-ethnic population. Prenat Diagn 2013;33:173–8.]Search in Google Scholar
[
136. Dovč-Drnovšek T, Klemenc P, Toplak N, Blejec T, Bricl I, Rožman P. Reliable determination of fetal RhD status by RHD genotyping from maternal plasma. Transfus Med Hemother 2013;40:37–43.]Search in Google Scholar
[
137. Yenilmez ED, Ozgünen FT, Evrüke IC, Tuli A. Noninvasive fetal RHD genotyping by multiplex real time PCR in maternal plasma. Int J Curr Med Res 2015;4:344–7.]Search in Google Scholar
[
138. Plešinac S, Plećaš D, Babović I. The determination of fetal RhD status from maternal blood in Serbia. Indian J Hematol Blood Transfus 2018;34:486–90.]Search in Google Scholar
[
139. Manfroi S, Calisesi C, Fagiani P, et al. Prenatal non-invasive foetal RHD genotyping: diagnostic accuracy of a test as a guide for appropriate administration of antenatal anti-D immunoprophylaxis. Blood Transfus 2018;16:514–24.]Search in Google Scholar
[
140. Bingulac-Popović J, Babić I, Đogić V, et al. Prenatal RHD genotyping in Croatia: preliminary results. Transfus Clin Biol 2021;28:38–43.]Search in Google Scholar
[
141. Pazourkova E, Zednikova I, Korabecna M, et al. Optimization of diagnostic strategy for non-invasive cell-free foetal RHD determination from maternal plasma. Vox Sang 2021;116:1012–9.]Search in Google Scholar
[
142. Elgun T, Musteri Oltulu Y, Gok Yurttas A, Agyuz U, Ozkal Molla F, Kilic U. Determination of Rh type and gender using circulating cell-free fetal DNA in early pregnancy of Rh negative women in turkey. Transfus Clin Biol 2023;30:324–8.]Search in Google Scholar
[
143. Amaral DR, Credidio DC, Pellegrino J Jr, Castilho L. Fetal RHD genotyping by analysis of maternal plasma in a mixed population. J Clin Lab Anal 2011;25:100–4.]Search in Google Scholar
[
144. Schmidt LC, Cabral AC, Faria MA, Monken F, Tarazona-Santos E, Martins ML. Noninvasive fetal RHD genotyping from maternal plasma in an admixed Brazilian population. Genet Mol Res 2014;13:799–805.]Search in Google Scholar
[
145. Ziza KC, Liao AW, Dezan M, et al. Determination of fetal RHD genotype including the RHD pseudogene in maternal plasma. J Clin Lab Anal 2017;31:e22052.]Search in Google Scholar
[
146. Blanco S, Giacomi VS, Slobodianiuk LG, et al. Usefulness of non-invasive fetal RHD genotyping towards immunoprophylaxis optimization. Transfus Med Hemother 2018;45:423–8.]Search in Google Scholar
[
147. Rather RA, Dhawan V, Saha SC. Non-invasive prenatal rhesus D genotyping using cell-free foetal DNA. Indian J Med Res 2019;150:62–6.]Search in Google Scholar
[
148. Sedrak M, Hashad D, Adel H, Azzam A, Elbeltagy N. Use of free fetal DNA in prenatal noninvasive detection of fetal RhD status and fetal gender by molecular analysis of maternal plasma. Genet Test Mol Biomarkers 2011;15:627–31.]Search in Google Scholar
[
149. Niguse B, Ermias M, Berhanu S, Abayneh L, Chakiso B, Rather RA. RHD exon 5, 7 and 10 targeted non-invasive prenatal screening of fetal Rhesus-D (RhD) in selected RhD negative pregnant women in Ethiopia. PLoS One 2022;17:e0265583.]Search in Google Scholar
[
150. Moezzi L, Keshavarz Z, Ranjbaran R, et al. Fetal RHD genotyping using real-time polymerase chain reaction analysis of cell-free fetal DNA in pregnancy of RhD negative women in south of Iran. Int J Fertil Steril 2016;10:62–70.]Search in Google Scholar
[
151. Ahmadi MH, Hantuoshzadeh S, Okhovat MA, Nasiri N, Azarkeivan A, Amirizadeh N. Fetal RHD genotyping from circulating cell-free fetal DNA in plasma of Rh negative pregnant women in Iran. Indian J Hematol Blood Transfus 2016;32:447–53.]Search in Google Scholar
[
152. Ahmadi MH, Pourfathollah AA, Rabiee M, Amirizadeh N. Noninvasive prenatal diagnosis of fetal RHD status using cell-free fetal DNA in maternal plasma. J Reprod Infertil 2022;23:128–34.]Search in Google Scholar
[
153. Ryczek E, White J, Carolan-Rees G. Implementation of high-throughput non-invasive prenatal testing for fetal RHD genotype testing in England: results of a cross-sectional survey of maternity units and expert interviews. Transfusion Med 2020;30:287–94.]Search in Google Scholar
[
154. Clausen FB, Barrett AN, Krog GR, Finning K, Dziegiel MH. Non-invasive foetal RhD genotyping to guide anti-D prophylaxis: an external quality assurance workshop. Blood Transfus 2018;16:359–62.]Search in Google Scholar
[
155. Visser GHA, Di Renzo GC, Spitalnik SL; FIGO Committee Safe Motherhood and Newborn Health. The continuing burden of Rh disease 50 years after the introduction of anti-Rh(D) immunoglobin prophylaxis: call to action. Am J Obstet Gynecol 2019;221:227.e1–e4.]Search in Google Scholar
[
156. Pegoraro V, Urbinati D, Visser GHA, et al. Hemolytic disease of the fetus and newborn due to Rh(D) incompatibility: a preventable disease that still produces significant morbidity and mortality in children. PLoS One 2020;15:e0235807.]Search in Google Scholar
